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Key Clinical Message
One of the strongest risk factors predisposing patients to breast cancer is a
positive family history. In our study, we describe a patient diagnosed with
multiple breast cancer tumors. Genetic analysis revealed a pathogenic variant in
BARD1, which is associated with an increased risk of developing certain types
of cancer.
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Introduction
Breast cancer is the most common form of cancer
among women. The majority of these cases are spo-
radic; however, hereditary risk factors are reported in
30% of patients [1, 2]. Through linkage analysis, candi-
date gene sequencing, and genomewide association stud-
ies (GWAS), many of the familial risk factors have
been identified and categorized as high, moderate, and
low risk, based on their probability of causing disease
[3]. Variants in high-risk genes, such as BRCA1 and
BRCA2, greatly increase the susceptibility of developing
breast and ovarian cancer. Additional studies have dis-
covered several moderate- and low-risk genes that also
lead to the development of breast cancer [4]. Clinical
genetic testing is frequently used to pinpoint these
causes. Understanding the origins of disease can assist
clinicians in the diagnosis, prognosis, and recommenda-
tion of therapy for these patients. In our case study,
we describe a patient with a positive family history of
cancer who had several recurrences of breast cancer
over the last 30 years of her life. Through genetic panel
screening, we discovered a deleterious variant in the
tumor suppressor, BRCA1-associated RING domain 1
(BARD1).
Case History
In this case, we present a 76-year-old female with a his-
tory of multiple bilateral breast cancers. Initially, she was
diagnosed with stage I invasive ductal carcinoma of the
left breast and underwent a lumpectomy plus axillary
lymph dissection at the age of 45. All lymph nodes were
negative. During postsurgery, she received adjuvant radia-
tion. Twenty years later, at 65 years of age, she was diag-
nosed with stage 0 ductal carcinoma in situ (DCIS) and
received a left mastectomy. Within a year, she had
returned with a swollen right axillary lymph node and
was then diagnosed with stage II breast cancer. She then
received a right lumpectomy with right axillary lymph
node dissection. A pathological evaluation of the removed
tumor revealed it to be an invasive ductal carcinoma
grade 3, negative for ER, PR, and HER2. Furthermore,
she had one positive lymph node out of six. After surgery,
she received adjuvant dose-dense chemotherapy for
approximately 5 months. This treatment included four
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cycles of Adriamycin followed by two cycles of Taxol, two
cycles of Abraxane, and finally four cycles of Cytoxan.
Subsequently, she also received adjuvant-like radiation
therapy to the right breast and regional lymphatics. It was
previously recommended that she undergo BRCA1/
BRCA2 variant analysis given her personal history of
breast cancer, which was negative. In late 2011, at the age
of 72, she was diagnosed with stage 1A right breast cancer
which included a 0.5-cm invasive ductal carcinoma grade
1 and an associated 0.8-cm DCIS. Further testing discov-
ered the carcinoma to be ER positive (over 50%), PR
positive (11–50%), and HER-2 negative by FISH with a
1.13 ratio but positive by immunohistochemistry. The
patient underwent a right mastectomy plus sentinel
lymph node biopsy. Lympho-vascular invasion and surgi-
cal margins were negative, and she began adjuvant endo-
crine therapy with letrozole.
Moreover, our patient describe an extensive family his-
tory of cancer, including a sister who died from breast
cancer at 76, a paternal aunt who died from uterine can-
cer at 65, and a paternal first cousin who died of uterine
cancer in her 70s (Fig. 1). Her paternal first cousin and
grandmother also had cancer, site unknown. Her father
and brother, who were both long-time smokers, both died
of throat cancer, aged 49 and 77, respectively.
Diagnosis and Investigations
Based on her recurring bouts of breast cancer and the
widespread family history of numerous cancers, she was
referred to the Department of Clinical Genomics to
undergo genetic testing. The Breast/Ovarian Cancer
Panel from GeneDx was recommended and revealed a
potentially pathogenic c.1921C>T variant (p.Arg641Ter)
in BARD1 (MIM*601593). This panel sequences 21 differ-
ent genes associated with hereditary breast and ovarian
cancer. (http://www.genedx.com/test-catalog/available-te
sts/breastovarian-cancer-panel/) Cancer risk associations
of BARD1 are not fully understood, although several
studies have suggested that variants in this gene may be
linked to an increased risk of developing breast and ovar-
ian cancers [5–8].
Discussion
A family history of breast cancer is one of the greatest
risk factors for disease. To date, there are over 30 differ-
ent genes linked to an increased risk of developing breast
cancer [1, 3, 9, 10]. The majority of familial cases are
caused by high-penetrance genes, such as BRCA1, BRCA2,
PTEN, and TP53. Other risk factor variants can be
Figure 1. Multiple cancer family pedigree. The proband (III-7) was diagnosed with multiple breast cancers. Genetic testing revealed a novel
BARD1 variant. Several cancers were also reported in various family members. Each affected family member is labeled by cancer and present age
or age at death.
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difficult to classify as familial due to reduced penetrance,
increased frequency within controls, and lack of molecu-
lar characterization. Therefore, it is essential to report
case studies of patient’s with variants in these newer,
moderate and lower risk genes.
In our patient, we identified a deleterious variant in
BARD1 denoted c.1921C>T. This substitution introduced
a premature stop codon and is predicted to cause loss of
normal protein function through either truncation or
nonsense-mediated mRNA decay. Genomic screenings of
large disease cohorts have reported this variant in triple
negative breast cancer, neuroblastoma, and pancreatic
cancer [11–15]. Our study is the first to provide a
detailed description of patient history, diagnosis, and
treatment in a patient harboring this particular variant,
which is considered pathogenic.
BARD1 was first discovered as a binding partner to
BRCA1 using a yeast two-hybrid screening [16]. In fact,
BARD1 and BRCA1 contain many structural similarities,
including an N-terminal RING finger domain and two
C-terminal BRCT domains. N-terminal binding of
BARD1 to BRCA1 forms a heterodimer complex which
stabilizes both proteins and acts as an E3 ubiquitin
ligase [17]. Furthermore, the association of BARD1 and
BRCA1 induces nuclear localization, DNA repair, and
tumor suppression [18]. In addition, BARD1 performs
several BRCA1-independent functions, which include
inhibition of polyadenylation of mRNA during DNA
damage as well as inducing apoptosis when it interacts
with p53 [19–21]. As BARD1 is involved in genomic
stability, disruptions of this protein due to genetic vari-
ants often lead to the development of various cancers
[11, 22]. Therefore, genetic testing of BARD1 in addition
to translational research is necessary to diagnose and
determine potential therapeutic options for patients with
pathogenic variants.
Conclusions
Due to the increased probability and recurrence of breast
cancer in patients with BARD1 pathogenic variants, early
and routine breast cancer screening such as yearly mam-
mograms and breast MRIs is recommended. Our patient
has had four episodes of breast cancer throughout her life
starting at the age of 45, with only 1 year between the
second and third diagnoses, revealing the importance of
screening these patients. Genetic testing and counseling
are also suggested for her adult children, who have a 50%
chance of inheriting this variant and passing it on to their
offspring. As our patient had an increased rate of cancer
within her extended family, it would have been of great
interest to test these members to determine whether other
cancers (i.e., uterine and throat) are also associated with
BARD1 variants. However, she is the only living member
still alive. Thankfully, routine screenings and follow-up
examinations can help prevent the spread or mortality
associated with familial breast cancer.
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